Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:46 PM
Ignite Modification Date: 2025-12-24 @ 4:46 PM
NCT ID: NCT05533450
Eligibility Criteria: Inclusion Criteria: 1. Be able to understand and sign the informed consent when accompanied by parents or guardians. 2. Age from 8 years old to15 years old. 3. The equivalent spherical lens of both eyes after ciliary muscle paralysis is -5.00D to -20.00D, the astigmatism is ≤-3.50D. 4. Willing to wear hard contact lenses, and able to wear only the hard contact lenses provided by the study as required and ensure adequate wearing duration. (6) Best corrected visual acuity of both eyes ≥ 0.8. Exclusion Criteria: (1) Allergic or intolerant to rigid contact lens or its care products or ciliary muscle paralysis drugs. Strabismus and/or amblyopia. (3) Those who have worn hard contact lenses in the past 30 days are using atropine, defocus frame lens, bifocal lens or progressive lens, acupuncture, etc. for myopia treatment. (4) Any clinically significant active eye disease, such as glaucoma, uveitis, chorioretinitis, central retinal artery or vein occlusion, and so on. (5) Patients with systemic diseases that may affect the wearing of hard contact lenses, such as hyperthyroidism, diabetes, mental illness, and so on. (6) are using drugs that affect their eye health. (7) History of eye injury or surgery. (8) Incapacitated or unable to follow the visitor as required. (9) Other conditions not suitable for inclusion as judged by the investigator.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 8 Years
Maximum Age: 15 Years
Study: NCT05533450
Study Brief:
Protocol Section: NCT05533450